Leading Cold Plasma medicine with the SteriPlas
The SteriPlas produces a repeatable, reliable, and highly efficacious Cold Plasma that has been proven in clinical trials and studies to destroy bacteria protected deep within biofilm.
Regardless of the resistance profile of bacteria, whether they are Gram-negative or Gram-positive, the physical mode of action of the SteriPlas Cold Plasma ensures the destruction of bacteria at the site of infection. This is particularly beneficial for difficult-to-treat or non-healing wounds such as diabetic foot ulcers, sternal wounds and LVAD infections. Where biofilm typically complicates the treatment options for these infections, the SteriPlas has been shown to fully heal patients even if they were not responding to antibiotic treatment to begin with thus saving limbs and lives.
All of this is achieved with the reputable safety of SteriPlas with no side effects reported.
Advanced Wound Care Summit 2023
We’re looking forward to presenting at the Advanced Wound Care Summit in Boston, USA in 2 weeks. Our Managing Director, Mary McGovern, will be presenting on our SteriPlas Cold Plasma and the strong benefits it brings to preventing amputations, reducing bed occupancy and saving lives.
Our presentation, “Cold Argon Plasma: A Powerful Tool for Infection Management, Biofilm Destruction and AMR” will explain our clinical evidence on the infection management of chronic, non-healing and infected wounds, impact of argon plasma on biofilm and the use of cold argon plasma in the fight against antimicrobial resistance.
We’re also open to meetings during the conference and would welcome your interest in our proven and patented technology. Send us an email at info@adtecplasma.com to learn more.
The Leader of Cold Plasma
There is expanding interest of our medical device for the treatment of chronic diabetic foot ulcers, deep sternal wounds and LVAD infections. We wish to remind you that if you are a Health Care Professional seeking to learn more about our medical device then please do get in contact with us. A member of our team will be able to show the full benefits and safety of using our medical device to treat these complicated conditions, with no side effects.
As Adtec Healthcare remains the leader of cold plasma medicine, we are lucky to be able to boast a wide clinical bibliography collection that really makes us stand out amongst the rest. We were the first company worldwide to do clinical trials of cold plasma on chronic wounds. Our clinical trials data has paved way in today’s medicine to show cold plasma as the go-to alternative for infection management.
If you are interested to bring the benefits of cold plasma to your patients, please email us at info@adtecplasma.com
SteriPlas to be presented at the ISDF conference
We’re looking forward to supporting Dr Pierides’ presentation at The International Symposium on the Diabetic Foot (ISDF) conference this Friday as he presents the strong benefits of our SteriPlas Cold Plasma medical device for the management of chronic Diabetic Foot Ulcers. His presentation, “DGH experience of using cold argon plasma in treating diabetic foot ulcers and its role in antibiotic stewardship” discusses the outcomes of 37 patients all of whom received once weekly SteriPlas treatment. The SteriPlas is shown to eliminate the use of antibiotics for chronic DFUs inhibited by multi-resistant bacteria. The unique physical mode of action that the SteriPlas delivers to the infection site ensures a total destruction of all antimicrobial resistant bacteria even if they are protected within biofilm.
For more information about our clinical evidence and medical device, please contact us at info@adtecplasma.com
How does the Adtec SteriPlas work so effectively?
Our patented cold plasma therapy utilises a physical mode of action approach delivered from an indirect microwave plasma source. Our cold argon plasma is an electrically charged and ionised gas that consists of charged particles, UV light and reactive oxygen and nitrogen species with the latter created as a by-product. They all work collectively to physically rupture the structure of bacteria even if they are protected within biofilm. Regardless of the type of bacteria, its resistance profile or whether they are Gram-positive or Gram-negative our cold plasma works quickly and effectively to destroy them. This has the leading advantage over conventional therapies such as antibiotics that rely on a chemical mode of action approach.
Although antibiotics have been a pivotal part of today’s medicine, they also contribute towards antimicrobial resistance rates particularly because bacteria can develop resistance such as those observed with diabetic foot ulcers that can often lead to amputations as a result.
However, as well as being fast-acting and effective, our cold plasma has shown that a primary or secondary resistance is unlikely to be developed due to its physical mode of action.
SteriPlas heals wounds quickly
Did you catch the leading Serbian media newspaper, Večernje Novosti, last week? Our SteriPlas was featured in the article, “Cold plasma heals wounds quickly” composed by Dr Zorić.
Dr Zoric has been using our cold plasma medical device to treat hard-to-heal and stalled wounds infected with biofilm. These problematic wounds have responded very well with our SteriPlas treatment and patients have been healed that were otherwise stalled by conventional therapies.
If you are within Serbia and interested to learn more about our medical device, contact our medical distributor Borf Health Care on info@borf.biz for more information.
Cold Plasma Diabetic Foot Ulcer Clinical Trial Published
Congratulations to Dr Cornelia Wiegand for her published clinical trial paper, “The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection”. This clinical trial paper features the use of our SteriPlas Cold Plasma medical device for the treatment of chronic DFUs infected with biofilm.
The parameters of this study were set much higher than a normal study, with there being a much higher standard of care given (3x per week) vs a typical outpatient setting of 1x weekly.
We wanted to show that even when chronic diabetic foot ulcers are subjected to more frequent outpatient visits with biopsies and swabs included (something not often collected during standard outpatient visits), SteriPlas Cold Plasma still prevails as the successful treatment method due to its physical mode of action and ability to kill all types of bacteria protected within biofilm.
Advanced Wound Care Summit Europe 2022
It was an honour to present at the Advanced Wound Care Summit Europe conference this week. Our extensive knowledge and library of clinical trials and our history as the experienced leader of Cold Plasma medicine was presented to the audience to bring light to the positive benefits of Adtec Cold Plasma devices.
If you would like to hear more about our efficacy and strengths for wounds, surgical site infections and medical dermatology, send us a PM or email us at info@adtecplasma.com
Presenting at The Advanced Wound Care Summit Europe
We’re looking forward to the Advanced Wound Care Summit Europe conference. On the 13th December, our Managing Director, Mary McGovern, will be presenting “Cold Plasma Medicine – Clinical Trials and Regulatory Challenges” where she will explain the importance of clinical trials to test the safety and efficacy of a medical device and the challenges that one can expect.
Since we were the first company worldwide to introduce cold plasma treatment on wounds in clinical trials, it comes to no surprise that we have good experience in this field. Adtec Healthcare boasts a wide collection of clinical trials and studies of our SteriPlas cold plasma medical device to authenticate the efficacy, safety and no side effects claims that we state. We have proven clinical efficacy of managing infections in diabetic foot ulcers and surgical site infections where other treatments have failed.
Evident to our success, this is why Adtec Healthcare’s clinical trials and studies are often referenced by other cold plasma manufacturers who do not have their own clinical studies. With patient safety in mind, clinical trials proving the efficacy must be completed by each manufacturer for the technology used in their device.
Poster presentation at the DFSG 2022
Did you see Dr Pierides' poster presentation yesterday at the DFSG Diabetic Foot Study Group conference? The poster featured the Adtec SteriPlas success in treating chronic infected diabetic foot ulcers.
The SteriPlas replaced the use of antibiotics for these heavily infected and impacted wounds and had shown remarkable success.
